Twenty-four cycling swamp buffaloes with normal reproductive histories and 2-3 months postpartum were used to investigate the effect of addition of estradiol-17 beta and human chorionic gonadotrophin (hCG) to the superovulation regime on the level of ovarian stimulation and embryo production. The estrous cycles of buffaloes were synchronized by prostaglandin injection and then divided into two groups for superovulatory treatment. Those in Group 1 (n = 12) received a implant containing 3 mg norgestomet (Syncro-Mate-B) for 9 days (insertion day is Day 0), with 4000 IU of equine chorionic gonadotrophin (eCG) and 500 micrograms cloprostenol i.m. given at Day 7. Group 2 (n = 12) received the same regime as Group 1, together with 7.5 mg estradiol-17 beta given in three intramuscular injections on Days 3, 5 and 7 in decreasing doses (4.0, 2.5 and 1.0 mg, respectively) and 5000 I.U hCG i.v. coincidentally with the first insemination. Estrus was monitored visually and by placing treated animals with bulls. Each animal was inseminated twice with frozen sperm after standing estrus. The numbers of corpora lutea (CL) and follicles greater than 8 mm in diameter were recorded via palpation per rectum at 6 days after implant removal. Two days later 11 animals from Group 2 and two from Group 1 were slaughtered for direct observation of ovarian responses and for embryo collection.

Beta-endorphin was measured in the plasma of pigs during late pregnancy and at different stages of the oestrous cycle. In pregnant animals, beta-endorphin secretion from uteroplacental tissues into the maternal circulation and the possible effects of oxytocin and the prostaglandin F2 alpha (PGF2 alpha) analogue cloprostenol on beta-endorphin release were determined. Plasma beta-endorphin concentrations in pregnant sows were significantly higher than in non-pregnant pigs. However, there were no significant changes in beta-endorphin values throughout the oestrous cycle. Because the increase in plasma beta-endorphin concentrations had occurred before luteolysis and onset of labour it could not be attributed to the stress of parturition. The surgical intervention of a laparotomy increased beta-endorphin release into peripheral plasma. Cloprostenol but not oxytocin caused an immediate increase in plasma beta-endorphin concentrations. At parturition, endogenous PGF2 alpha may be involved in the regulation of beta-endorphin secretion. Concentrations of beta-endorphin in the jugular and uterine vein plasma were not significantly different, and so it would appear that beta-endorphin in the plasma of pregnant sows is not of uteroplacental origin. In conclusion, changes in the concentration of beta-endorphin in peripheral plasma, associated with pregnancy but not the oestrous cycle, exist in pigs. Hence a physiological function of peripheral opioid peptides in the periparturient sow is feasible.

Laboratory trials were conducted to study the effect of various concentrations of cloprostenol on the motility and morphological changes of the acrosomes of boar spermatozoa. As found, a cloprostenol concentration of 250 ng per ml of semen to 2500 ng per ml of diluted semen has no adverse effect on the motility of spermatozoa and on the morphological changes of their acrosomes. The concentration of 5000 ng of cloprostenol (in the Oestrophan Spofa product) per 1 ml of diluted semen negatively influences the motility of spermatozoa. An insemination dose of 100 ml of diluted sperm treated with 500 ng of cloprostenol was used for the artificial insemination of 152 sows; 166 sows of the same farm inseminated with untreated semen were used as controls. No gilts were included in the trial. Out of the 152 test sows, 113 conceived after the first insemination, i.e. 74.35%, and the average litter size was 10.04 piglets. In the control group, 125 sows delivered their litters, i.e. 75.30% of the total number, the average litter size being 9.96 piglets. Comparing the reproduction parameters of the experimental and control groups it can be said that the treatment of an insemination dose with 500 ng of cloprostenol immediately before insemination had no influence on the pregnancy rate and on the size of litters.

Romney ewes were artificially inseminated at the oestrus after treatment with PMSG on Day 12 of the cycle, Cloprostenol on Day 14, or both. PMSG resulted in increased numbers of ovulations and large follicles but Cloprostenol had no effect alone or with PMSG, PMSG and Cloprostenol alone led to reduced proportions of eggs fertilized, and PMSG also reduced the proportion of ewes with fertilized eggs. The distribution of eggs in the reproductive tract indicated more rapid egg transport in ewes treated with PMSG. A greater proportion of eggs was recovered from the uterus in ewes in which oestrus was first detected at night. Cloprostenol, as administered to PMSG-treated ewes in this trial, offered no advantage for the preparation of donor ewes for egg transfer.

The aim of this study was to evaluate the "male effect" at the end of protocol with prostaglandins (PG) on estrus synchronization of hair sheep during breeding season (November-December) in Yucatan, Mexico. Twenty female Pelibuey sheep (weighting 38.2 ± 1.6 kg and body condition score of 2.5 ± 0.5) were randomly distributed in two groups (n = 10). Group T1 (control, PG), two doses of 50 μg of cloprostenol with 12 days between applications were applied; in the second group T2 (PG-ME), ewes received the same PG protocol plus the introduction of a male at the end of treatment. The interval of end treatment-onset of estrus was analyzed using survival test; the number of sheep with presence/absence of estrus was analyzed using Fisher's exact test. Ewes in estrus for groups T1 and T2 were 5 vs. 8, respectively. No significant differences were found as regards the interval end of treatment-onset of estrus (P>> 0.05), as well as in total proportion of ewes with estrus and likewise in the duration of it (P>> 0.05). We conclude that the protocol based on double dose of PGF2α with interval of 12 days combined with the male effect is efficient to induce luteolysis and estrus synchronization in hair sheep.

Prostaglandin F(2α) and its analogues (PGF) are widely used in equine reproductive practice. The interval from PGF treatment to ovulation (ITO) varies greatly with a range from 2 to 16 days. Clinical observation suggests that mares mated and ovulated soon after PGF treatment may have poor fertility. Reproductive records of 329 cyclic Thoroughbred mares were analysed retrospectively. The following parameters were analysed: (i) use of cloprostenol; (ii) ITO and (iii) number of ovulations per cycle. According to these parameters, mares were classified into four groups. (i) mares with spontaneous ovulations, n = 57; (ii) mares induced with cloprostenol and ITO = 4-7 days, n = 77; (iii) ITO = 8-10 days, n = 89 and (iv) ITO = ≥ 11 days, n = 106. Differences in pregnancy (PR) and multiple ovulation (MO) rates among groups were tested using chi-squared test. PR rates for groups 1-4 were: 73.7%, 46.7%, 64% and 71.7% respectively (p < 0.05). Groups 1 and 2 had lower (p < 0.05) MO rate (24.6% and 20.8%) than groups 3 and 4 (40.4% and 44.3%). It appears that ovulation soon after PGF-induced luteolysis is detrimental to PR rates. It was found highly significant that in cloprostenol-treated mares, the MO rate was enhanced without subsequent increase in multiple pregnancies.

Cloprostenol, 100 micrograms, given intramuscularly to the nanny, with 50 micrograms 10 hours later, precipitated parturition in goats after 36 +/- 1 hours (mean +/- SEM), when administered at 137 +/- 0.5 days gestation. All kids were born alive and survived to weaning. Milk yield over 40 weeks post partum was not significantly different from that after spontaneous parturition. Three hundred micrograms cloprostenol (200 micrograms with 100 micrograms 10 hours later) also initiated parturition at 137 +/- 0.5 days gestation but caused a significant (P less than 0.01) suppression of lactation. Cloprostenol-induced parturition in more than one pregnancy had no adverse effects except for an increased incidence of placental retention, which was treated successfully with intrauterine pessaries containing oestrogen. During the first eight days after spontaneous parturition efficiency of milk secretion was inversely related to udder mass, suggesting a gradual maturation of the secretory alveolar epithelium over this time. When parturition was induced by cloprostenol there was a four to eight day delay before the establishment of this relationship which appeared essential for a successful lactation. Cloprostenol proved to be a useful tool for the control of parturition in goats, having applications to both general animal husbandry and for the study of mammary development and secretory competence.

In microminipigs, estrus induction with abortion treatment, which is typically performed between 25 and 40 days after mating, is not always successful. Thus, the authors hypothesized that it may be more difficult to induce estrus by treating microminipigs approximately 40 days after mating. Accordingly, in this study, estrus induction was performed with abortion treatment in four microminipigs as follows: 0.3 mg of cloprostenol, a prostaglandin F2-alpha analog, was administered (day 0); after 24 h, 0.15 mg of cloprostenol and 250 IU of equine chorionic gonadotrophin were administered intramuscularly and simultaneously (day 1); after 96 h, 120 IU of human chorionic gonadotropin was injected intramuscularly (day 4). These treatments were compared at two different stages of pregnancy: early treatment (26.5 ± 0.7 days) and late treatment (38.3 ± 0.8 days). In the early treatment, all four microminipigs exhibited estrus on day 5, whereas in the late treatment, estrus was observed clearly in only two pigs on day 6 and slightly in 1 pig on day 10, whereas it was unclear in 1 pig. These results suggest that it is difficult to induce estrus with abortion treatment in microminipigs at approximately 40 days after mating.

Experiments were carried out under conditions existing in industrial swine complexes with two groups of experimental sows: I group -- consisting of 17 sows injected on the 108th and 109th day of pregnancy with 175 g cloprostenol, and II group -- consisting of 145 sows injected on the 110th, 111th, 112nd and 113th day of pregnancy. On 125 sows of 110--111 day of pregnancy a reduced single dose application of 150 g cloprostenol was tested. Studies were performed on the period to farrowing following cloprostenol injection, the duration of farrowing, the changes in physiological behaviour, the number of viable and unviable new born piglets, the results following weaning of offspring at the age of 28 days and on the economic evaluation of the technology of forced synchronized and programmated farrowing in industrial swine complexes. It was established that the synthetic analogue of prostaglandine F2L (cloprostenol) applied once by intramuscular injection at a rate of 175 g per sow on the 110--113th day of pregnancy has a luteinizing effect and leads to forced synchronized farrowing of 75--80% of the sows, 27 +/- 5 h post treatment. Similar results were obtained by a reduced rate of 150 g cloprostenol. Synchronized farrowing provides an opportunity for simultaneous weaning of equated piglet groups and contributes for better labour organization and veterinary service. Shortening the pregnancy period below the 110th day is not feasible physiologically and economically.

The objective of this study was to test the hypothesis that PGF2alpha is associated with abortion and changes in plasma Zn, Cu, and Fe concentrations in cows and mares in their first trimester of pregnancy. Eleven pregnant cows were infused with endotoxin (n = 5) or endotoxin plus an inhibitor of cycloxygenase, flunixin meglumine (n = 6). Blood was collected over a 5-d period. Additionally, 4 mares were treated every 24 h with cloprostenol sodium and blood was collected hourly until abortion. Plasma Zn, Cu, and Fe were determined. Three of five cows treated with endotoxin aborted, but none of the six cows treated with endotoxin and flunixin meglumine aborted. Aborting cows had lower plasma Zn (P = 0.048) over the 5-d study period compared with the nonaborting cows. The changes in Zn corresponded to release of PGF2alpha. All 4 mares aborted and plasma Zn concentrations were lower (P = 0.008) and Cu/Zn was higher (P = 0.02) 12 h after cloprostenol treatment. Plasma Zn may be a useful biomarker for risk of spontaneous abortion, and the decline in plasma Zn may be caused by PGF2alpha.

We studied the effects of gonadotrophins and prostaglandin (PG) F(2alpha) on ovulation in gilts. Twenty-eight gilts were induced to ovulate using 750 IU pregnant mares serum gonadotrophin (PMSG) and 500 IU human chorionic gonadotrophin (hCG), administered 72 h apart. At 34 and 36 h after hCG, gilts received injections of either 500 mug or 175 mug PGF(2alpha) (<em>cloprostenol</em>), or had no injections. Laparotomies were performed at 36 h (<em>cloprostenol</em> gilts) or 38 h (controls) after hCG injection. The ovaries were examined and the proportion of preovulatory follicles that had ovulated (ovulation percent) was determined at 30 min intervals for up to 6 h. The number of gilts in which ovulation was initiated and the ovulation percent increased (p<0.001) with time, but was not affected by treatment. Many medium sized follicles (</=6 mm) were also observed to ovulate, or to exhibit progressive luteinization without overt ovulation, during the surgical period. A discrepancy between numbers of preovulatory follicles and corpora lutea suggests that luteal counts may not be an accurate assessment of ovulation rate following gonadotrophic stimulation.

Concentrations of beta-endorphin and oxytocin were measured in plasma of cows before, during and after parturition. The effect of the PGF2 alpha analogue cloprostenol on beta-endorphin and oxytocin release was investigated. During parturition, there were marked, parallel increases in beta-endorphin and oxytocin concentrations. Both hormones were released in an episodic manner in conjunction with uterine and abdominal contractions. It is therefore likely that factors stimulating oxytocin release also enhance beta-endorphin secretion. This suggests a role of labour or labour-associated hormones in stimulating peripheral beta-endorphin release. Cloprostenol caused an immediate, pronounced increase in plasma beta-endorphin and oxytocin concentrations.

Several lines of evidence suggest that follicular granulosa cells give rise to the large luteal cells of the corpus luteum in the sheep. To further investigate this suggestion, numbers of granulosa cells in preovulatory follicles were estimated by morphometric methods for comparison with a previous estimate of numbers of large luteal cells (9.6 +/- 0.9 x 10(6)). Preovulatory follicles from five Corriedale ewes were obtained after synchronization of the oestrous cycle with the prostaglandin analogue cloprostenol. Morphometry was undertaken using light microscopy of plastic-embedded tissue sectioned at 1 micron. Mitotic index in the membrana granulosa was 0.05 +/- s.e.m. 0.05%. Mean follicular diameter was 6.25 +/- 0.25 mm and there were 7.68 +/- 0.53 x 10(6) granulosa cells per follicle. These results demonstrate a similarity between the number of granulosa cells per follicle and the number of large luteal cells per corpus luteum and thus support the hypothesis that large luteal cells are derived from granulosa cells.

The aim of this study was to evaluate the progesterone (P4) release profile provided by eight commercial intravaginal P4 devices, as well as the effect of circulating P4 concentrations produced exclusively by these devices on the development of the dominant follicle (DF) in non-lactating multiparous Holstein cows. All cows were submitted to the same experimental design starting with the insertion of a reused P4 device (2 g - original P4 load) for 7 d, followed by two treatments of cloprostenol sodium (PGF; 0.482 mg), 24 h apart, 6 and 7 d after device insertion. Just before device removal, a Norgestomet ear implant was inserted and, 2 d later (Day 0), simultaneously to Norgestomet withdrawal, cows received one of the tested intravaginal devices and 2 mg of estradiol benzoate (EB) im. In Exp.1 (n = 22; three replicates), cows were randomized to receive: CIDR (1.38 g); PRID-Delta (1.55 g); Prociclar (0.75 g); or Repro sync (2 g). In Exp. 2 (n = 29; four replicates), cows were randomized to receive: Cue-Mate (1.56 g); DIB 0.5 (0.5 g); DIB (1 g); PRID-Delta (1.55 g); or Sincrogest (1 g). Blood samples were collected before P4 device insertion (Day 0), 12 h later and daily over 15 d (1 d after P4 device removal). Ultrasound examinations were performed to evaluate growth of the DF on Days 0, 7, 8, 9, and 10. Results are presented as mean ± SEM and differences were considered when P ≤ 0.05. Overall, the circulating P4 profile and mean circulating P4 over 10 d differed among treatments. However, no effects were observed on the DF diameter and follicular growth rate from Day 7-10 after P4 device insertion. In Exp. 2, devices that provided higher circulating P4 concentrations were associated to a slower DF growth during the treatment period. Finally, this study provided a better understanding of the P4 release profile produced by intravaginal P4 devices as well as their effect on circulating P4 concentrations and DF development in non-lactating Holstein cows.

Keywords: Bos taurus; Dairy cow; Device; Dominant follicle; Steroid hormone.

Background: Information on the impact of hormonal protocols for cervical dilation on the quality of ovine embryos is scarce.

Methods: To compare the quality of embryos after cervical dilation protocol, ewes (n = 64) were allocated into either a treated group (100 μg estradiol benzoate intravenous and 0.12 mg cloprostenol intramuscularly, 12 hours before embryo collection plus 100 iu oxytocin intravenous 15 minutes before the collection procedure) or a control group (saline). Luteal function was analysed using ultrasonography and P4 measurement. Some collected embryos were frozen/thawed for gene expression, others were cultured in vitro, frozen/thawed for gene expression, and the remaining embryos were fixed for the apoptosis test (TUNEL test).

Results: The treatment reduced fluid (p=0.04) and structure (p=0.03) recovery rates, but the morphological quality, development stage, and apoptosis incidence of the embryos were not affected by treatment. The corpora lutea of the control group had greater blood perfusion (p = 0.002) and greater P4 concentrations at 6, 9, and 12 h after the treatment (p < 0.0001). The expression of BAX, BCL2, PRDX1, and HSP90 genes were not affected by the treatment. However, the embryos in the treated group had fewer NANOG and OCT4 transcripts than control embryos (p = 0.008; p = 0.006, respectively). After culture, there was no difference between the groups in any gene.

Conclusion: The hormonal protocol for cervical dilation reduced the efficiency of embryo collection. In addition, the treatment induced luteolysis and a transient alteration of embryo gene expression, however there were no detectable changes in embryo morphological quality, development stage, or incidence of apoptosis.

Keywords: apoptosis; corpus luteum; embryo production; progesterone; qRT-PCR; sheep.

In cattle there are two types of the corpus luteum (CL): homogeneous (CL_hom) and cavitary (CL_cav). Although they are considered equal in their hormonal activity, the function of the CL_cav is questioned by many veterinarians. In consequence, females with the CL_cav are considered less valuable for assisted reproductive techniques such as embryo transfer (ET), where recipients with the CL_hom are preferred. The aim of our study was to compare the two types of CLs regarding morphological endpoints, serum progesterone (P4) concentrations and final pregnancy rate (PR) in recipient heifers after ET. The morphological type of the CL and the final PR after ET of 432 Holstein Friesian heifers were analyzed. Oestrus was synchronized with two i.m. inj. of 0.5 μg cloprostenol 14 days apart. The ET took place on the day 7 of the estrous cycle, only animals with visible oestrum were chosen for the procedure. Clinical and transrectal US examinations of ovaries were performed on the day of ET. The presence of the CL_hom or CL_cav was determined, and the CL diameter and cross-sectional area were measured. If present, measurements of the cavities were also taken. Only embryos recovered immediately prior to the ET at the morula or blastocyst stage were transferred to the randomly chosen recipient that underwent initial selection regardless of the CL morphology. Additionally, from randomly selected heifers (N = 53, CL_hom = 33; CL_cav = 20) blood samples for serum P4 concentration analysis were collected. Pregnancy was determined by transrectal palpation 2 months after ET. The medium-sized CL_cav was larger in diameter (P < 0.001) and cross-sectional area (P < 0.01) than the CL_hom (mean ± SD) - 23.29 ± 3.6 mm and 419.57 ± 135.01 mm² compared to 21.87 ± 3.57 mm and 384.73 ± 145.46 mm², respectively. The mean diameter and cross-sectional area of the cavity were 10.2 ± 4.36 mm and 97.59 ± 71.13 mm², respectively. The volume of both types of CLs was similar (P = 0.3). The mean serum P4 concentration was 8.84 ng/ml, higher (P < 0.0001) for females with the CL_cav (11.31 ng/ml) than for those with the CL_hom (7.15 ng/ml). The PR was 36.1%, higher (P < 0.05) for recipients with the CL_cav (47.7%) compared to the CL_hom (29.9%). The presence of a CL_cav in the recipient heifers did not negatively affect the potential of the CL to maintain pregnancy. On the contrary, the CL_cav may give the embryo better chances of surviving the time of pregnancy recognition and in consequence, may have a positive effect on PR in heifers.

Keywords: Cattle; Cavity; Corpus luteum; Embryo transfer; Heifers.

Intramuscular injection of the naturally occurring prostaglandin F2alpha (PGF2alpha) to sexually mature female pigs induces luteolysis and rapidly elicits a behavioural response consistent with pre-partum nest-building. Intramuscular injection of the synthetic prostaglandin F2alpha (cloprostenol) also induces luteolysis but no nest-building behaviour is observed. The effects of PGF2alpha, but not cloprostenol, on nest-building behaviour may be mediated via peripheral PGF2alpha receptors (FP) or via direct action on central FP receptors. We have previously shown FP receptor mRNA to be localized in porcine paraventricular nucleus (PVN), supraoptic nucleus (SON) and pars dorso-medialis of the suproptic nucleus (SOD), suprachiasmatic nucleus, choroid plexus and anterior and intermediate pituitary lobes. In this experiment, we examined hypothalamic expression of the immediate early genes c-fos and c-jun mRNA after treatment with PGF2alpha or cloprostenol. Twenty-one 8-month-old nulliparous female pigs (gilts) were injected intramuscularly with a luteolytic dose of PGF2alpha (15 mg), cloprostenol (175 microg) or saline control, their behaviour was recorded and they were killed 60 min later. Coronal hypothalamic sections and control ovarian tissues were incubated with 45-mer oligonucleotide probes complementary to porcine c-fos and c-jun genes using standard in situ hybridization histochemistry techniques. Significantly higher c-fos and c-jun mRNA expression was found in PGF2alpha-treated compared to saline or cloprostenol-treated pigs in the PVN, SON and SOD. Significantly higher c-fos and c-jun mRNA expression was found in corpus lutea of PGF2alphaand cloprostenol-treated pigs compared to saline controls. Treatment with PGF2alpha induced nest-building behaviour whereas treatment with cloprostenol and saline did not. This suggests that PGF2alpha, or one of its metabolites, and not cloprostenol, crosses the blood-brain barrier and acts directly on hypothalamic receptors to mediate its effect on nest-building behaviour.

This study examined the effects of exogenous hCG administration on ovarian function and pregnancy rates in estrous-induced dairy goats during the transition into the breeding season. Eighty-six Toggenburg does received 60 mg of medroxyprogesterone acetate intravaginal sponge for 6 d plus 200 IU of equine chorionic gonadotropin and 30 μg of d-cloprostenol i.m. 24 h before sponge removal, and were then bred for 96 h. Seven days (D7) after first mating the does received either 1 mL of saline (the control group, n = 43) or 300 IU of hCG (the hCG-treated group, n = 43) i.m. Transrectal ovarian ultrasonography (B-mode and color Doppler) was performed on D7, D13, D17, and D21 and ultrasonographic pregnancy detection on D30. Pregnancy rate was higher (P < 0.05) in hCG-treated goats (90.7%; 39/43) than that in control animals (74.4%; 32/43). Accessory luteal structures (ALSs) were detected in 46.5% (20/43) of hCG-treated does. All hCG-treated does that had ALSs and 82.6% of goats without ALS post-treatment remained pregnant. The total luteal area increased (P < 0.05) from D7 to D13 in pregnant animals of both groups, whereas mean vascular area declined (P < 0.05) by D21 in all nonpregnant does. Serum progesterone concentrations increased (P < 0.05) on D21 in pregnant goats of both groups, but they were related to changes in luteal tissue content only in control does throughout the present study. Mean daily numbers of small- and medium-sized antral follicles decreased (P < 0.05) only in pregnant animals of both groups with a decline in medium follicle numbers occurring earlier in hCG-treated (D13) compared with control does (D17). To summarize, a single dose of hCG given on D7 after estrus was followed by a decrease in the number of medium-sized antral follicles in gestating hCG-treated does, induced the formation of ALSs in ~47% of all hCG-treated does, and significantly increased the pregnancy rate in estrous-induced Toggenburg goats in the transition to the breeding season.

Keywords: Conception rate; Goat; Ovary; Progesterone; Ultrasonography; hCG.

This study was conducted to compare efficacy of treatments with EB or GnRH and different quantities of exogenous progesterone (P₄) for synchronization of time of ovulation on follicular growth and pregnancy in lactating dairy cows. In Experiment 1, 40 cows were treated with EB or GnRH and 1.9 or 3.0 g of P₄ via progesterone-containing intravaginal devices (IVPD; D0), two doses of PGF_2α on D7, GnRH on D9, and TAI on D10. In Experiment 2, 1,440 cows were treated with EB or GnRH and 1 g IVPD on D0, cloprostenol, eCG and EB on D7. Cows in estrus by 48 h were AIDE, and non-estrous cows were administered GnRH and TAI 60 h after IVPD removal. Non-estrous cows were AIDE 72 h after IVPD removal. In Experiment 1, P₄ was greater on D7 for cows treated with GnRH than those treated with EB. The dominant follicle was larger for cows treated with GnRH than those treated with EB. In Experiment 2, for estrous cows, pregnancy per AI was greater in cows AI at 48 h compared to 60 h after IVPD removal for cows treated with GnRH, and greater with AI at 60 h after IVPD removal compared to 48 h in EB-treated cows. In non-estrous cows, there was no effect on pregnancy. In conclusion, treatment with GnRH compared with EB resulted in increased P₄ regardless of amount of exogenous P₄, and there were differential proportions of estrous cows pregnant depending on time of AI after IVPD removal.

Keywords: Dairy cows; Estradiol; Estrous synchronization; GnRH; Progesterone.

Over the past few decades, the luteolytic dose of prostaglandin F_2α (PGF_2α) and its analogs, used to synchronize estrus for fixed-time insemination in dairy cattle, have remained unchanged. Given the beneficial effects of PGF_2α on a young corpus luteum and on multiple ovulations in a fixed-time insemination protocol, and its therapeutic abortive effects on multiple ovulations in pregnant cows, we propose the use of a double PGF_2α dose or two PGF_2α treatments 24 hours apart. Ultrasonography procedures serve to identify luteal structures and may therefore help to determine the best PGF_2α dose to improve the fertility of high-producing dairy cows.

Keywords: Additional corpora lutea; Cloprostenol; Double ovulation; Fixed-time artificial insemination (FTAI); Twin pregnancy.

This study was conducted in ewes to assess effects of human chorionic gonadotropin (hCG) administration after imposing an estrous induction treatment regimen. Ewes (n = 115) were treated with a 60 mg medroxyprogesterone-intravaginal-sponge for 6 d plus 200 IU of equine chorionic gonadotropin (eCG) im and 37.5 μg d-cloprostenol im 36 h before sponge removal (Day 0). After natural mating, ewes having at least one corpus luteum (CL; n = 108) were administered either 1 mL of saline (G-Control; n = 53) or 300 IU of hCG (G-hCG; n = 55) on Day 7.5 after sponge removal (Day 0). Ovarian ultrasonography and blood collection were performed on Days 7.5, 13.5, 17.5, 21.5, and 30.5. Accessory CL (aCL) were observed in 81.5 % (G-hCG) and 0.0 % (G-Control) of ewes (P = 0.0001). Diameter, area, and volume of luteal tissue were greater (P < 0.05) in G-hCG from Day 13.5 to 30.5. Progesterone (P₄) concentrations were greater (P < 0.05) on Days 13.5, 17.5, 21.5 and 30.5 for ewes of the G-hCG group. Pregnancy percentage was similar (P = 0.25) between groups [47.1 % (G-control) compared with 60.0 % (G-hCG)], although total number of lambs produced by estrous synchronized ewes was greater (P = 0.005) in ewes of the G-hCG group (90.9 % compared with 66.0 %). In conclusion, hCG administration 7.5 days after sponge removal from Morada Nova ewes during the non-breeding season is an effective treatment to induce aCL formation, improve luteal tissue biometry and P4 concentrations, and to enhance the total number of lambs born.

Keywords: Accessory corpora lutea; Luteal blood flow; Luteal vascularization; Ovarian ultrasonography; Progesterone; hCG.

The aim of this study was to evaluate the outcomes of an early resynchronization protocol (Resynch) initiated at different timepoints after timed artificial insemination (TAI) and with unknown pregnancy status. Holstein cows (n = 164) were submitted to the following TAI protocol: D0, insertion of an intravaginal progesterone (P4) device and 2 mg im estradiol benzoate (EB); D8, removal of P4 device and treatment with 0.5 mg im sodium cloprostenol (PGF); D9, 0.1 mg im Lecirelin (LEC); and D10, TAI1. Cows were then randomly assigned to Resynch protocols starting either on day 20 (Resynch20D, n = 82) or 25 after TAI1 (Resynch25D, n = 82) with the insertion of a new P4 device and EB treatment. In both groups, P4 device was removed on day 8 after the beginning of Resynch, the same day of pregnancy diagnosis by ultrasonography. In pregnant cows there was no further action. Non-pregnant cows were treated with 0.5 mg im PGF, had a blood sample collected for serum P4 analysis and we measured and recorded the size of the largest follicle and the presence or absence of a corpus luteum (CL). One day later, cows were treated with 0.1 mg im LEC and TAI2 occurred 12-14 h later. The diameter of the largest follicle and serum P4 were compared between groups by ANOVA for the main effects of treatment, presence of a CL, and their interaction, whereas pregnancy per artificial insemination (P/AI) and the percentage of cows with a CL on the day of ultrasonography were analyzed using the Chi-square test. Follicle diameter on day 8 of Resynch was greater for cows in the Resynch20D group compared with Resynch25D (15.9 ± 3.9 vs 12.2 ± 2.5 mm, respectively; P = 0.046). The Resynch25D group had a greater percentage of cows with a CL (51.9 vs 18.9%, respectively; P = 0.0008) and higher serum P4 (2.8 ± 1.1 vs 1.7 ± 0.8 ng/mL; P = 0.041) at the end of the protocol compared with Resynch20D. P/AI at TAI1 was 35.4 and 36.6% (P > 0.10) for cows enrolled in Resynch20D and Resynch25D groups, respectively. P/AI to TAI2, after Resynch protocols, was greater in Resynch25D than Resynch20D (44.2 vs 22.6%, respectively; P < 0.05). In conclusion, starting an early resynchronization protocol 25 days after TAI increases P/AI compared with starting 20 days after TAI, and this was associated with a presumed greater proportion of cows with a functional CL at the moment of P4 device removal.

Keywords: Artificial insemination; Bovine; Reproductive efficiency; TAI protocol.

In tropical areas, local goats are often reported as being able to reproduce throughout the year, whereas an influence of season is found to be a factor when importing different dairy breeds. In these areas, oestrus synchronisation in goats is of interest for both technical (synchronisation of kidding, adjustment to forage availability or to continuous milk supply) and genetic reasons (dissemination of improved genotypes by AI). The use of a progestagen vaginal sponge combined with equine chorionic gonadotrophin (eCG)-cloprostenol injections remains an efficient tool to achieve synchronisation in temperate and tropical zones. However, the oestrus synchronisation treatments currently used for goats in tropical regions were originally developed for goats bred in temperate regions. For this reason, several alternative possibilities for improving the efficiency of the hormonal treatment are evaluated. Oestrus synchronisation with luteolytic agents is efficient (resulting in more than 70% of goats in oestrus) and it takes into account female cyclicity. In developing regions of the tropics, the use of buck teasing appears to be a promising approach to control oestrus and ovulation. The use of this technique provides 60% of females in oestrus within 5 days of introducing the bucks. Considering the availability of nutrients as the ultimate regulator of reproduction in the tropics, the control of nutritional condition is essential before the use of hormonal treatments for oestrus synchronisation in goats bred in these regions takes place.